| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,385 | 0,536 | 08:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.03. | AcouSort AB: AcouSort receives prepayment of royalties | 233 | GlobeNewswire (Europe) | AcouSort AB today announced the signing of an amendment to its license and distribution agreement with the leading blood-gas analyzer company, Werfen. Under the amendment, Werfen will prepay minimum... ► Artikel lesen | |
| ACOUSORT Aktie jetzt für 0€ handeln | |||||
| 25.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2025 | 137 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.October - December 2025 for the GroupNet sales amounted to TSEK 2,459 (1,221)Result before tax... ► Artikel lesen | |
| 19.12.25 | AcouSort AB: AcouSort and MFX enter a collaboration to streamline future cell therapy manufacturing | 1.112 | GlobeNewswire (Europe) | AcouSort AB today announced it has entered a collaboration with MFX, a UK-based developer of next-generation scalable bioreactor platforms, to evaluate if AcouSort's technology can be paired with MFX's... ► Artikel lesen | |
| 15.12.25 | AcouSort AB: Stefan Blomsterberg elected new Chairman of the Board of AcouSort | 205 | GlobeNewswire (Europe) | AcouSort AB today announced that Stefan Blomsterberg has been appointed new Chairman of the Board, effective January 1, 2026.
Stefan Blomsterberg currently holds the position as CEO of CELLINK Bioprinting... ► Artikel lesen | |
| 26.11.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - September 2025 | 208 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
July - September 2025 for the GroupNet sales amounted to TSEK 1,248 (1,198)Result before tax... ► Artikel lesen | |
| 19.11.25 | AcouSort AB: AcouSort and Danish SeeQ Diagnostics sign technology evaluation agreement | 270 | GlobeNewswire (Europe) | AcouSort AB today announced it has signed a technology evaluation agreement with the Danish diagnostics company SeeQ Diagnostics concerning the evaluation of AcouSort's blood/plasma separation technology... ► Artikel lesen | |
| 22.09.25 | AcouSort AB: AcouSort receives new order boosting Central European collaboration | 211 | GlobeNewswire (Europe) | AcouSort AB today announced it has received a third order from a Central European company that develops diagnostic systems and medical devices. The company evaluates AcouSort's novel technology for... ► Artikel lesen | |
| 27.08.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - June 2025 | 178 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
April - June 2025 for the GroupNet sales amounted to TSEK 1,551 (961)Result before tax amounted... ► Artikel lesen | |
| 28.05.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2025 | 312 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2025 for the GroupNet sales amounted to TSEK 1,595 (1,357)Result before tax amounted... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 52,08 | +0,46 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,370 | +2,39 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH | 170,10 | -1,05 % | RBC stuft Sartorius Stedim Biotech auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Sartorius Stedim mit einem Kursziel von 210 Euro auf "Outperform" belassen. Analyst Charles Weston nahm mit Blick auf die jüngsten Quartalszahlen... ► Artikel lesen | |
| BIOLIFE SOLUTIONS | 19,900 | -7,01 % | BioLife Solutions, Inc.: BioLife Solutions Reports First Quarter 2026 Financial Results | Total revenue of $27.5 million, up 25% over Q1 2025
GAAP gross margin and non-GAAP adjusted gross margin of 64%
GAAP net income of $1.2 million and non-GAAP adjusted... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,445 | -0,18 % | Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge? | ||
| CRESCENT BIOPHARMA | 15,400 | 0,00 % | Crescent Biopharma to present CR-001 trial data at ASCO meeting | ||
| IMMUNOVANT | 34,160 | +0,09 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,650 | -0,07 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,620 | 0,00 % | Tango Therapeutics Shares Fall 17% | ||
| QIAGEN | 30,095 | 0,00 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 80,61 | 0,00 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| SUMMIT THERAPEUTICS | 17,475 | +0,03 % | Bernstein downgrades Summit Therapeutics stock rating on trial concerns | ||
| PRAXIS PRECISION MEDICINES | 350,56 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,010 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,110 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen |